Turtle Cameron, CEO, reported an open-market or private sale at Spyre Therapeutics, Inc. involving 957.000000 shares for an estimated $30451.74. Reported holdings after the transaction were 671583.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.42 to $32.05, inclusive. The Reporting Person undertakes to provide to th…
Includes 145,198 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date.
Includes 633 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on August 15, 2024.
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.48 to $33.35, inclusive. The Reporting Person undertakes to provide to th…
0 other filings
0 recent txs